Santa Clara, CA – According to filings with the U.S. Securities and Exchange Commission, AIxMed is raising $12,649,981.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Samuel Chen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AIxMed
AIxMed AI-based cell biology intended to discover deep insights in cells. The company is currently operating in stealth mode.

To learn more about AIxMed, visit http://www.aixmed.com/

Contact:
Samuel Chen, President and Chief Executive Officer
510-571-0623
samuel.chen@aixmed.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved